 |
Mesoblast Limited (ASX:MSB) in Position of Considerable Strength
AUG 24, 2011 10:00 - Article Views: 1,374
Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today provided its full year financial results. The company stated that it had substantial funds of A$263.2 million at 30 June 2011. Mesoblast recorded revenue and other income of A$120.9 million and a profit before tax of A$92.2 million. |
 |
 |
Mesoblast Limited (ASX:MSB) Performed First Minimally Invasive Procedure for Lumbar Disc Repair
AUG 22, 2011 08:32 - Article Views: 1,233
Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the first minimally-invasive lumbar disc procedure had been successfully performed in the Phase 2 clinical trial of its proprietary adult Mesenchymal Precursor Cell product for the treatment of low back pain and degenerative disc disease. The outpatient procedure lasted less than 20 minutes, with the patient fully awake and under light sedation. The patient was shortly discharged and there were no complications. |
|
 |
Mesoblast Limited (ASX:MSB) Heart Failure Trial Selected for Presentation in Special Session of American Heart Association Annual Conference Melbourne, Australia on 15 August 2011
AUG 15, 2011 09:40 - Article Views: 1,215
Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that its heart failure clinical trial has been chosen by the American Heart Association to be featured at its 2011 annual conference in Orlando, Florida, in the "Clinical Science: Special Reports" session on November 14. More than 17,000 international cardiovascular specialists are expected to attend the conference. |
|
 |
Mesoblast Limited (ASX:MSB) Receive FDA Clearance for Phase 3 Bone Marrow Transplant Trial
JULY 7, 2011 09:23 - Article Views: 1,295
Global regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration to begin a Phase 3 clinical trial for bone marrow regeneration in patients with blood cancers. FDA clearance was obtained within the 30-day minimum time period after Mesoblast filed its Phase 3 Investigational New Drug submission. |
|
|
US Food and Drug Administration Clears Mesoblast Limited (ASX:MSB) Phase 2 Trial to Treat Degenerative Disc Disease
JUNE 29, 2011 09:22 - Article Views: 1,919
Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration to begin a Phase 2 clinical trial of its proprietary adult Mesenchymal Precursor Cell (MPC) product for the treatment of degenerative disc disease. |
|
 |
Mesoblast Limited (ASX:MSB) Key Product Franchises Featured at Nomura Asia Equity Forum
JUNE 14, 2011 12:26 - Article Views: 1,388
Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), was featured today at the 8th Nomura Asia Equity Forum being held in Singapore. Mesoblast was the only Australian company to present at the respected Asian investor forum. |
|
 |
Mesoblast Limited (ASX:MSB) Revascor Increases Blood Supply to Damaged Heart Muscle
JUNE 9, 2011 09:39 - Article Views: 1,798
Results from Mesoblast Limited's (ASX:MSB) (PINK:MBLTY) cardiovascular clinical trials were featured at the Goldman Sachs 32nd Annual Global Healthcare Conference in California today. |
|
 |
Mesoblast Limited (ASX:MSB) To Present At Goldman Sachs (NYSE:GS) 32nd Annual Global Healthcare Conference
JUNE 6, 2011 10:19 - Article Views: 2,214
Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that its Chief Executive, Silviu Itescu, will present at the Goldman Sachs (NYSE:GS) 32nd Annual Global Healthcare Conference in the United States. Mesoblast joins Resmed and Ramsay Healthcare as the only Australian companies participating in the global investor forum. |
|
|
Mesoblast Limited (ASX:MSB) Key Patents Granted In United States Strengthen Commercial Rights And Broaden Clinical Indications
MAY 24, 2011 09:40 - Article Views: 1,538
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the company's product development strategy has been significantly strengthened by novel composition of matter claims granted by the United States Patent and Trade Mark Office in two distinct patent families to which Mesoblast has exclusive worldwide commercial rights. |
|
|
